The invention concerns pharmaceutically useful compounds of the formula I, in which R1, R2, R3, n, m and Het have any of the meanings defined herein, and their pharmaceutically-acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processess for the manufacture of the novel compounds and the use of the compounds in medical treatment.
本发明涉及式 I 的药用化合物(其中 R1、R2、R3、n、m 和 Het 具有本文所定义的任 何含义)及其药学上可接受的盐类,以及含有它们的药物组合物。这些新型化合物具有内皮素受体拮抗剂活性,可用于治疗内皮素
水平升高或异常起重要致病作用的疾病或病症。本发明还涉及新型化合物的生产工艺以及这些化合物在医疗中的应用。